Antineoplastics
1
Reactions 500 - 7 May 1994 Antineoplastics Peripheral nerve disorders: incidence study Peripheral neuropathy is a common adverse effect of antineoplastic therapy for cancer, say researchers from Germany. They studied the long-term neurological adverse effects of antineoplastic therapy in patients treated for Hodgkin’s disease or testicular cancer. Subjective neurological symptoms were experienced by 27/73 (37%) patients a median of 8 years after treatment for Hodgkin’s disease. However, peripheral neuropathy was confirmed in only 10 of these patients. Patients with peripheral neuropathy were more likely to have received a median cumulative vincristine dose of > 20mg, compared with patients without peripheral neuropathy. Peripheral neuropathy was found in 14/115 (12%) patients treated for testicular cancer with cisplatin-based antineoplastic therapy after a median follow-up of 6 years. The median cumulative dose of cisplatin in these patients was much higher than in patients who did not experience any neurological adverse effects (650 vs 370 mg/m 2 ). Patients who developed peripheral neuropathy also tended to receive a higher total dose of etoposide than those who did not. Bokemeyer C, et al. Peripheral neuropathy following cancer chemotherapy. TumorDiagnostik und Therapie 14: 232-237, Dec 1993 - Germany 800260249 1 Reactions 7 May 1994 No. 500 0114-9954/10/0500-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 500 - 7 May 1994
Antineoplastics
Peripheral nerve disorders: incidence studyPeripheral neuropathy is a common adverse effect of
antineoplastic therapy for cancer, say researchers fromGermany. They studied the long-term neurological adverseeffects of antineoplastic therapy in patients treated forHodgkin’s disease or testicular cancer.
Subjective neurological symptoms were experienced by27/73 (37%) patients a median of 8 years after treatment forHodgkin’s disease. However, peripheral neuropathy wasconfirmed in only 10 of these patients. Patients with peripheralneuropathy were more likely to have received a mediancumulative vincristine dose of > 20mg, compared withpatients without peripheral neuropathy.
Peripheral neuropathy was found in 14/115 (12%) patientstreated for testicular cancer with cisplatin-based antineoplastictherapy after a median follow-up of 6 years. The mediancumulative dose of cisplatin in these patients was much higherthan in patients who did not experience any neurologicaladverse effects (650 vs 370 mg/m2). Patients who developedperipheral neuropathy also tended to receive a higher totaldose of etoposide than those who did not.Bokemeyer C, et al. Peripheral neuropathy following cancer chemotherapy.TumorDiagnostik und Therapie 14: 232-237, Dec 1993 - Germany 800260249
1
Reactions 7 May 1994 No. 5000114-9954/10/0500-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
